Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy

Lingyun Li, Amyn Rojiani, Dietmar W. Siemann

Research output: Contribution to journalArticle

128 Scopus citations

Abstract

Purpose: The aim of this study was to evaluate the antitumor efficacy of combretastatin A-4 disodium phosphate (combretastatin prodrug) in the rodent KHT sarcoma model either alone or in combination with radiation therapy. Methods: KHT tumors were grown in C3H/HeJ mice. Combretastatin A-4 prodrug was injected intraperitoneally at doses ranging from 10 to 100 mg/kg. Tumors were irradiated in unanesthetized mice using a 137Cs source. Tumor response to combretastatin A-4 prodrug was assessed by histological evaluations as well as an in vivo to in vitro cell survival assay. Results: Histological evaluation showed morphological damage of tumor cells within a few hours after drug treatment, followed by extensive central necrosis. Administering increasing doses of combretastatin A-4 prodrug to tumor- bearing mice resulted in a dose-dependent increase in cell killing irrespective of whether the tumors were irradiated or not. When combined with radiation, a 100 mg/kg dose of combretastatin A-4 prodrug reduced tumor cell survival 10-500-fold lower than that seen with radiation alone. Further, the shape of the cell survival curve observed following the combination therapy suggested that including combretastatin in the treatment had a major effect on the radiation-resistant hypoxic cell subpopulation associated with this tumor. Conclusion: The present results demonstrated that in the KHT sarcoma, combretastatin A-4 prodrug caused rapid vascular shutdown, a concentration- dependent direct cell killing, and effective enhancement of the antitumor effects of radiation therapy.

Original languageEnglish (US)
Pages (from-to)899-903
Number of pages5
JournalInternational Journal of Radiation Oncology Biology Physics
Volume42
Issue number4
DOIs
StatePublished - Nov 1 1998
Externally publishedYes

Keywords

  • Combretastatin
  • KHT sarcoma
  • Vascular targeting

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy'. Together they form a unique fingerprint.

  • Cite this